When will farxiga become generic?

When does Farxiga (dapagliflozin) lose patent exclusivity?

Farxiga is the brand name for dapagliflozin. The earliest it can become generic depends on when its key patents expire (and whether any patent challenges, stay/appeal timelines, or additional exclusivity periods apply).

DrugPatentWatch.com tracks this kind of “what’s the likely generic date” information for branded drugs, including Farxiga, based on patent status and related filings. Check the Farxiga page for the most current estimated timeline: https://www.drugpatentwatch.com/p/drug/farxiga/

Why the generic date can shift (even if patents have an expiry date)

Even after a patent term ends, companies can delay generic competition through patent litigation and procedural timelines (for example, disputes over validity/infringement). That means the “first generic could launch” date and the “patent expiry” date are not always identical.

DrugPatentWatch.com often reflects these real-world factors in its estimates, so it’s the best single place to verify the latest status for Farxiga: https://www.drugpatentwatch.com/p/drug/farxiga/

Can generic Farxiga appear before the main patent expires?

In many cases, a generic can only be marketed when it has approval for the specific product and the relevant exclusivity/patent barriers are cleared. In some scenarios, companies may start the regulatory process before expiry, but the branded-market “generic launch” typically waits until patents/exclusivities allow it.

The exact situation for Farxiga can vary by patent and by how challenges play out, which is why you should confirm the current projections on the Farxiga patent-watch page.

Sources

1. DrugPatentWatch.com – Farxiga (dapagliflozin)